Building Families Worldwide

Per Falk

President and Chief Science Officer

18th January 2019 CONFIDENTIAL

2

Our History

Eva and Frederik Paulsen

3

Our Mission Statement

Driven by its entrepreneurial spirit and enabled by a decentralised organisational setup,

Ferring will harness its world-class competencies in science and business with other

innovative technologies to create solutions for patients and doctors. By developing an

understanding of people’s needs, we will deliver personalised healthcare solutions,

integrating pharmaceutical products with diagnostics, data, devices, education and

support services to optimise health outcomes.

Ferring will be the world-leading, most trusted healthcare company in

reproductive medicine and women’s health, and a leader in specialty areas within

gastroenterology and urology. Each of us at Ferring will contribute to providing

innovative solutions to help people live better lives. We will devote significant research

and development investment to new therapeutics, life cycle management and next

generation healthcare solutions.

As a privately owned, specialty healthcare company that operates globally, Ferring will

grow revenues at a rate that is 50% faster than the industry average. We will strive for

efficiencies in our business and create flexibility to invest in opportunities to build our

future.

We are, and will continue to be, part of a transparent and aligned company. We strive to

best address the needs of patients, stakeholders and customers by collaborating across

functions, experimenting and sharing our practices, and continuously learning. We are

always guided by the Ferring Philosophy.

4

Our global presence

Distribution in 110

countries

Marketing and sales

in 56 countries

11 R&D centers

12 manufacturing sites

5

Innovation from conception to delivery

Menorrhagia

Down

regulation

Stimulation

ImplantationLuteal support

Pre-mature

labour

Induction

of labor

Post Partum

Hemorrhage

Lactation

Phase II

Phase II

Phase III

ResearchResearch, Device,

Geographical expansion

Research

Anovulation

Regulatory

Geographical expansion

PABAL® (OT agonist)

MISODEL® (PGE1 vaginal insert)

PROPESS® (PGE2 vaginal insert)

TRACTOCILE® (OT/V1a antagonist)

LYSTEDA® (Anti-fibrynolytic)

GONAPEPTYL® (GnRH agonist)

LUTINUS® (vaginal progesterone)

MILPROSA®

MENOPUR® (HP-hMG)

LUTREPULSE® (LHRH s.c. pump)

CHORAGON® (u-hCG)

NORPROLAC® (quinagolide hydrochloride)

REKOVELLE® (follitropin delta)

Ps female indications only noted on slide, these products also have male indications

Gynaecology

Fertility

Obstetrics

6

Therapeutic area revenue contributions

€1.9 billion*

Reproductive

Medicine &

Women’s Health

Orthopaedics

Urology

Gastroenterology

Endocrinology

9%

5%

23%

16%

46%Other

1%

*2017 revenue

7

R&D Investment per therapeutic area

*2017 revenue of €1.9 billion

~17% of revenue*

21%

20%

38%

22%REPRODUCTIVE MEDICINE

AND WOMEN’S HEALTH

UROLOGY

OTHER

GASTROENTEROLOGY

22%

38%

20%

21%

8

Our mission

• Ferring has been developing treatments for mothers and

babies for over 50 yearsFerring will be the world-leading, most

trusted healthcare company in reproductive

medicine and women’s health

9

Our ambition

Pioneer a new era in fertility

where all potential parents are

empowered to build families

10

Our strategy

Optimizing our current assets in close collaboration with our customers to ensure delivery of maximum value to providers and patients

Developing and launching next generation therapies in Fertility, Obstetrics and Gynaecology indications impacting fertility

Improving access to care addressing patient, provider, payer, policy makers and societal needs by developing meaningful solutions in partnerships

Collaborations

12

ReproUnion

• Collaboration between a network of 16 clinical and research units within the Capital Region of Denmark and Ferring Pharmaceuticals

• 16 Clinical/Research Units

• ±15 PI’s

• 25 Projects

• Investment of €15 million over three years

• 25 PhD students/Postdocs (19/6)

13

Ferring Institute of Reproductive Medicine

25% of couples in China are

affected by infertility1 vs. 17% of

couples worldwide2

• Ferring’s long-term collaboration with CAS includes the creation of the Ferring Institute of Reproductive Medicine (FIRM) in Beijing, China

• Collaboration focuses on scientific research in reproductive medicine and women’s health that may lead to new treatments for fertility and pregnancy-related conditions

• Aim is to advance basic and translational research through the development of novel product candidates and therapeutic strategies

• FIRM will explore novel technologies in stem cell and regenerative medicine, and identify new targets for drug-discovery

1. Zhou Z, Zhang D, et al. Epidemiology of infertility in China: a population based study. British Journal of Obstetrics and

Gynaecology 2017. Available at: https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/1471-0528.14966.

2. European Society of Human Reproduction and Embryology. ART Factsheet. February 2018. Available at:

https://www.eshre.eu/Press-Room/Resources.aspx Last accessed: May 2018.

3. https://www.youtube.com/watch?v=sqG_7V7hwB0

14

Collaborations in personalised medicine and genomics

15

Reducing Maternal Mortality - CHAMPION

The global clinical trial compared the effectiveness and

safety of Ferring's heat-stable carbetocin

to oxytocin in the prevention of postpartum haemorrhage

(PPH) after vaginal births1,2

MSD for Mothers funded the trial and the Human Reproduction

Program at the World Health Organization

conducted the trial. Involving nearly 30,000 women

in 10 countries,1,2 CHAMPION is the largest clinical trial

ever conducted in PPH

We believe we could save thousands of lives and improve

the quality of life of women and their families by delivering

heat-stable carbetocin to countries that need it most

Excessive bleeding after childbirth, known as PPH, is

the leading direct cause of maternal mortality worldwide3

99% of deaths from PPH occur in low- and

lower-middle-income countries4

14,000,000women develop

PPH

every year4

480,000mothers died

from PPH

between

2003–20093

1. Widmer M, et al. Room temperature stable carbetocin for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally: study protocol for a randomized controlled trial. Trials 2016; 17(1):143. doi:

10.1186/s13063-016-1271-y

2. Australian New Zealand Clinical Trial Registry. Available at: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=366743 Last accessed: May 2018.

3. Say L, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health 2014 Jun;2(6):e323-33.

4. World Health Organization. Priority diseases and reasons for inclusion. Postpartum haemorrhage. Available at: http://www.who.int/medicines/areas/priority_medicines/Ch6_16PPH.pdf Last accessed: May 2018.

CHAMPION (Carbetocin Haemorrhage Prevention)

Questions?